Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. - Wikidata - thesis-toulmin - TriplyDB

Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.

Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.

http://www.wikidata.org/entity/Q33232246

about

Applications of urinary proteomics in biomarker discovery Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care A urinary Bcl-2 surface acoustic wave biosensor for early ovarian cancer detection.Human body fluid proteome analysis.Liquid chromatography-mass spectrometry: a tool for proteome analysis and biomarker discovery and validation.Urine collection and processing for protein biomarker discovery and quantification.Lysine-based zwitterionic molecular micelle for simultaneous separation of acidic and basic proteins using open tubular capillary electrochromatography Early detection of ovarian cancer Functional protease profiling for diagnosis of malignant disease.Urinary signatures of Renal Cell Carcinoma investigated by peptidomic approaches.Excretion of urinary orosomucoid 1 protein is elevated in patients with chronic heart failure.Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin An extensive targeted proteomic analysis of disease-related protein biomarkers in urine from healthy donors.Identification of low-abundance proteins via fractionation of the urine proteome with weak anion exchange chromatography.Potential markers for detection and monitoring of ovarian cancer.fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.Urinary protein biomarkers in the early detection of lung cancer.Application of proteomics to cancer early detection Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms.Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates.Use of electroporation and reverse iontophoresis for extraction of transdermal multibiomarkers.-The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.Ovarian cancer biomarkers: current options and future promise.Elevated expression levels of ANXA11, integrins β3 and α3, and TNF-α contribute to a candidate proteomic signature in urine for kidney allograft rejection.Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients.Eosinophil associated genes in the inflammatory bowel disease 4 region: correlation to inflammatory bowel disease revealed.Unrestrictive identification of post-translational modifications in the urine proteome without enrichment.Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer.Recent technical strategies to identify diagnostic biomarkers for ovarian cancer.Proteomic profiling of urine for the detection of colon cancer.Diagnostic potential for urinary proteomics.The proteogenomic path towards biomarker discovery Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer.Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.Potential Urinary Protein Biomarker Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic Hyperplasia Patients.A proteomic analysis of IVF follicular fluid in women <or=32 years old.Deconvoluting the 'omics' for organ transplantation Urinary proteomic profiling for diagnostic bladder cancer biomarkers.Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis.

P2860

Q27010368-85C698C7-EEF4-4440-BF3E-0632A52391A9 Q30449569-13A7F54E-4A25-4852-AB02-A157043C0169 Q30463771-EE7C4F41-532E-48A3-8AB3-D8D782AEA2B6 Q33262623-8C951238-46FD-45B3-9E0A-D6088ED35B18 Q33457379-0B57C9DF-F5AC-4208-849C-EA568FE81DAE Q33780855-C821FA6E-EBC0-4E01-A511-D3B956BDA595 Q33986147-90A79A83-E9CE-4B9E-B437-993B7132F0FA Q34094731-C1EEEB33-B9C1-4995-A819-5CA4DBEF43B4 Q34116114-7BE0B967-C81A-42B1-A277-5B8CED8B9BF3 Q34155959-C9A83325-AF20-4EF9-8056-0A6ABBBF1C9C Q34172662-77BE4DBB-47F3-4776-AF05-FE61B15915C6 Q34387861-B53552D0-EC47-4703-B2F0-978C9FBC5BE4 Q34749242-745965A4-5D9E-48CC-A29D-F3BD7184B7BD Q34817332-3704E140-FB51-4228-A659-98A7C016CC8B Q34960174-9C26E7AD-6537-40B8-B864-6B6CDD2579AB Q35021181-54F0C838-FE67-43C9-AEB3-CDDFE632E091 Q35044516-31B6158D-01B4-4619-8292-D574A96E06F9 Q35053031-347BE725-1767-459D-8A82-D22E3675B4D4 Q35166076-57778BFB-E6B8-46FC-B6A7-D7073D00DAB5 Q35661217-F91261EF-5E65-4B39-A81B-6D35E71BFF7E Q35787516-62749B2C-A838-40BE-863B-924565D9C00D Q36016842-B14304DD-9664-44E1-B6DB-B7929486A553 Q36029907-1BF5BF24-18DD-465B-9ACF-781D45FD03A6 Q36054395-C8049DAB-81F5-4EFD-92C2-AC5739DB089B Q36241222-5661F9A1-0A0F-4BB3-B041-F858D5AA9F69 Q36316587-7A99E84F-147B-4CD2-8205-8AB5E3255380 Q36429822-193667E6-8CB6-4139-860E-A0EB5B0C404E Q36649243-1538604C-5C4F-481C-B6E6-1470BEC6C063 Q36686826-9E2D93EE-7D0F-4C6E-8759-223C68948952 Q36731399-A3E93BC6-6574-410C-857C-5BCB4FFE2A77 Q36736959-4D4333BC-43E0-4912-8C2D-7302A31AC774 Q36745677-F7E2DDFB-00E1-4303-89F8-49A0434A829D Q36952173-928E80CA-CC03-43B0-B0E4-649BF94B30D2 Q37376643-BDBDE002-EA68-44F3-8FC2-E6F810EEB95A Q37484011-1D8987F1-2AFA-48A5-B2B6-BE9FA81E1803 Q37540974-9FE443F8-7400-46B0-B2D5-740C3BCA5852 Q37561962-A0723BEA-BFD0-4EAB-8D10-07F54912A881 Q37567360-73F5E774-74BD-4ADD-944B-6373355AF3CD Q37610310-A70EEEF4-1A2A-4D5E-BC16-61853DCBAEB3 Q37706040-0BA227B2-6FB5-4AC8-AB85-A77D8FA96CAF

P2860

Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.

http://www.wikidata.org/entity/Q33232246

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Proteomic-based discovery and ...... s for ovarian cancer in urine.

@ast

Proteomic-based discovery and ...... s for ovarian cancer in urine.

@en

type

label

Proteomic-based discovery and ...... s for ovarian cancer in urine.

@ast

Proteomic-based discovery and ...... s for ovarian cancer in urine.

@en

prefLabel

Proteomic-based discovery and ...... s for ovarian cancer in urine.

@ast

Proteomic-based discovery and ...... s for ovarian cancer in urine.

@en

P1433

Q33232246-77B6DE00-1831-48C3-8C20-BC2C33F24B89

P1476

Q33232246-2690CC6F-E107-4279-83DA-2FF0154D78CC

P2093

Q33232246-1C8E01F0-4938-48A6-9A83-81CE536D0922

Q33232246-3426D523-6265-496E-AB8B-8F1CC4A40C93

Q33232246-422B7DDA-7AE5-4BA2-9B98-874858BB83F5

Q33232246-5D6D9BCB-C335-4F7A-9235-9090D770B837

Q33232246-644F6A1A-8EB3-44D6-9508-2BF354AC92CC

Q33232246-65049A3F-0F8D-42A2-A222-7C54780F9D9E

Q33232246-79ABE7BD-B51C-4BE9-BC4F-8D3252E918E7

Q33232246-A56C89C8-4564-41A0-8A8C-FF1AA4311775

Q33232246-DBB78272-8F5C-4F4F-AEDF-B742B4F07EF6

Q33232246-FA37F96B-C01E-46BC-9ACF-AB0559079C29

P304

Q33232246-199919EB-109F-4CF7-8269-10A3D120C20E

P31

Q33232246-AB78705D-EF6B-49C7-8F06-79F984278565

P356

Q33232246-D7C63EBA-F023-4028-AF52-9AD93FAA0B77

P407

Q33232246-AA9AA378-33B9-4AFF-9574-7F266965E50C

P433

Q33232246-15960186-D006-483E-9F72-288B3AE4C6D9

P478

Q33232246-0E191EDE-147A-4B12-8712-71835D68F71B

P577

Q33232246-59F5D647-D679-41CB-BA91-2FD9EDC5DCEE

P698

Q33232246-448E924E-0B12-42D9-BF09-5F94B58A0A06

P921

Q33232246-17478229-FFA0-416B-96C1-576F29885584

Q33232246-FDFAF9A5-3C6F-4B90-9A37-D239C37FFDB8

P356

1078-0432.CCR-05-0461

P1433

Clinical Cancer Research

P1476

Proteomic-based discovery and ...... s for ovarian cancer in urine.

@en

P2093

Allison Vitonis

http://www.w3.org/2001/XMLSchema#string

Bin Ye

http://www.w3.org/2001/XMLSchema#string

Dale Edwards

http://www.w3.org/2001/XMLSchema#string

Daniel W Cramer

http://www.w3.org/2001/XMLSchema#string

Helene F Rosenberg

http://www.w3.org/2001/XMLSchema#string

Nora K Horick

http://www.w3.org/2001/XMLSchema#string

Patrick Sluss

http://www.w3.org/2001/XMLSchema#string

Ross S Berkowitz

http://www.w3.org/2001/XMLSchema#string

Samuel C Mok

http://www.w3.org/2001/XMLSchema#string

Steven Skates

http://www.w3.org/2001/XMLSchema#string

P304

432-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-05-0461

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16428483

http://www.w3.org/2001/XMLSchema#string

P921